PMID: 9180599May 1, 1997Paper

WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys

The American Journal of Tropical Medicine and Hygiene
N ObaldiaG D Shanks

Abstract

The compound WR 238605 is a primaquine analog being developed by the U.S. Army as an antimalarial drug. Currently, there is no established treatment for Plasmodium vivax parasitemias that are not cured by chloroquine. This study tested WR 238605, chloroquine, and their combinations against a chloroquine-resistant strain of P. vivax (AMRU 1) in Aotus monkeys. A total dose of 3 mg/kg of WR 238605 given at a dosage of 1 mg/kg/day for three days cleared patent parasites in all eight monkeys but recrudescence of parasitemia occurred 15-25 days after initiation of treatment. A total dose of 9 mg/kg of WR 238605 over a three-day period cured all three monkeys of their infections. A total dose of 30 mg/kg of chloroquine did not clear patent infections in three monkeys, whereas a total dose of 60 mg/kg generally (two of three) cleared patent parasitemia but did not cure. Whereas total doses of 30 mg/kg of chloroquine or 3 mg/kg of WR 238605 given alone failed to cure, both drugs given in combination at these dosages cured two of three infections. These results indicate that WR 238605 may be an alternative treatment for chloroquine-resistant vivax malaria.

Citations

Jan 1, 2000·Journal of the Royal Society of Medicine·W Peters
Oct 3, 2002·Tropical Medicine & International Health : TM & IH·Giao T PhanPiet A Kager
Oct 16, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas S WalshSornchai Looareesuwan
Nov 20, 2004·Transactions of the Royal Society of Tropical Medicine and Hygiene·Peter Nasveld, Scott Kitchener
Aug 21, 2013·Parasitology·Alice S ButterworthKatharine R Trenholme
Oct 22, 2014·Antimicrobial Agents and Chemotherapy·Geoffrey W BirrellMichael D Edstein
Jun 27, 2018·Antimicrobial Agents and Chemotherapy·Nicanor ObaldiaDennis E Kyle
Nov 30, 2019·Future Medicinal Chemistry·Ishan WadiAbhinav Sinha
Feb 23, 2020·Expert Review of Vaccines·Manuel Alfonso PatarroyoDarwin A Moreno-Pérez
Nov 18, 2005·The American Journal of Tropical Medicine and Hygiene·Alejandro Jordan-VillegasSócrates Herrera
Nov 1, 2006·Current Opinion in Infectious Diseases·Babu L Tekwani, Larry A Walker
Apr 28, 2007·Expert Opinion on Investigational Drugs·Maryanne Crockett, Kevin C Kain
Jul 15, 2009·Clinical Microbiology Reviews·J Kevin Baird
Oct 27, 2004·Antimicrobial Agents and Chemotherapy·J Kevin Baird
Sep 13, 2006·Antimicrobial Agents and Chemotherapy·G S DowK S Smith
May 10, 2018·MBio·Nicanor ObaldiaMatthias Marti
Dec 18, 2019·Antimicrobial Agents and Chemotherapy·Fiona J McCallumMichael D Edstein
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·J L VennerstromW K Milhous
Nov 21, 2017·Trends in Parasitology·Jennifer S Armistead, John H Adams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.